2016
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, Stone GW. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology 2016, 117: 1877-1883. PMID: 27131611, DOI: 10.1016/j.amjcard.2016.03.034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAspirinBlood PlateletsClopidogrelCoronary Artery DiseaseDrug Therapy, CombinationDrug-Eluting StentsEuropeFemaleHemorrhageHumansIncidenceMaleMiddle AgedMyocardial IschemiaPercutaneous Coronary InterventionPlatelet AggregationPlatelet Aggregation InhibitorsProspective StudiesRegistriesRisk AssessmentRisk FactorsSurvival RateTiclopidineUnited StatesConceptsHigh platelet reactivityDrug-Eluting Stents studyMajor adverse cardiac eventsAdverse cardiac eventsDual antiplatelet therapyPlatelet reactivityAntiplatelet therapyMajor bleedingCause mortalityCardiac eventsMultivariate adjustmentStent studiesWorld Health Organization criteriaImpact of anemiaPresence of anemiaPercutaneous coronary interventionDrug-eluting stentsIschemic riskBleeding riskClinical confoundersCoronary interventionAnemic patientsClinical outcomesHemoglobin levelsStudy cohort
2014
Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial
Ertelt K, Généreux P, Mintz GS, Brener SJ, Kirtane AJ, McAndrew TC, Francese DP, Ben-Yehuda O, Mehran R, Stone GW. Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. Cardiovascular Revascularization Medicine 2014, 15: 375-380. PMID: 25288517, DOI: 10.1016/j.carrev.2014.09.002.Peer-Reviewed Original ResearchConceptsPremature coronary artery diseaseST-elevation myocardial infarctionPrimary percutaneous coronary interventionCoronary artery diseaseHORIZONS-AMI trialPercutaneous coronary interventionFamily historyCoronary interventionArtery diseaseIndependent predictorsClinical outcomesClinical profileMyocardial infarctionFinal TIMI 3 flowMyocardial blush grade 2Less diabetes mellitusTIMI 3 flowFuture cardiovascular eventsPrognosis of patientsShorter symptom onsetMore dyslipidemiaCardiovascular eventsCurrent smokersSymptom onsetDiabetes mellitus